(Z)-1-(3-(4-methylbenzyl)-5-morpholinobenzo[d]thiazol-2(3H)-ylidene)propan-2-one | 1169756-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (Z)-1-(3-(4-methylbenzyl)-5-morpholinobenzo[d]thiazol-2(3H)-ylidene)propan-2-one
• 英文别名: (1Z)-1-[3-[(4-methylphenyl)methyl]-5-morpholin-4-yl-1,3-benzothiazol-2-ylidene]propan-2-one
• CAS: 1169756-39-1
• 化学式: C₂₂H₂₄N₂O₂S
• 分子量: 380.511
• InChiKey: CUSVDQLMAHOHID-XKZIYDEJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  58.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DES KINASES DE TYPE CDC2 (CLK) ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2009085226A2

  公开（公告）日：2009-07-09

  Provided herein are compounds which are CDC2-Like Kinase (CLK) inhibiting compounds and methods of use thereof. The CLK-inhibiting compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, ocular disorders, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a Clk-inhibiting compound in combination with another therapeutic agent.